From medical exoskeleton to headless industrial humanoid
Headquarters
Paris
Employee
—
Models here
1
Listings
0
Wandercraft was founded in Paris in 2012 and initially focused exclusively on one problem: how to enable a paralyzed person to walk freely again without relying on crutches for support. This question led to the creation of Atalante, the first self-balancing exoskeleton now in use at European rehabilitation clinics. In addition to its headquarters in Paris, the company maintains a location in New York.
The technical core remains the same across all products: a control system that keeps a two-legged body stable while walking without requiring human balance input. On the medical side, there is Atalante NX, a clinical exoskeleton, and Eve, a home device. On the industrial side, since 2025 there is Calvin-40, a deliberately headless humanoid that carries up to 40 kilograms and is operated via speech and a visual language model. It is controlled via NVIDIA Jetson with Isaac and ROS 2; the hands are interchangeable grippers, suction cups, or dexterous hands depending on the task.
Wandercraft is one of the few European robotics companies whose humanoid works not at trade shows but in an active automotive factory. Since April 2025, a Calvin-40 has been hauling tires for the Renault 5 at the Renault Douai plant; Renault plans to expand its fleet to 350 units within eighteen months. In early September 2026, the company reported twelve major customers from automotive manufacturing, logistics, retail, healthcare, and defense. Regular series production is scheduled to begin in the first half of 2027.
Calvin-40
Industrial humanoid · 40 kg payload · headless
Atalante NX
Self-balancing exoskeleton for clinics
Eve
Exoskeleton for personal use
Founded in Paris with the goal of enabling paralyzed individuals to walk freely without hand support.
First clinical deployments of the self-balancing Atalante exoskeleton.
Introduction of the Calvin-40 industrial humanoid, first series deployment at Renault Douai plant starting in April.
Announcement of twelve major customers in early September, series production scheduled for 2027.
No distribution partner known in Switzerland. Inquiries are handled directly through the manufacturer in Paris; the exoskeletons are in use at several European rehabilitation clinics.